Population aging has emerged as one of the most significant demographic trends of the twenty-first century. Advances in healthcare, nutrition, and living standards have substantially increased life expectancy worldwide, resulting in a growing proportion of elderly individuals [1]. Although increased longevity is a positive development, it is accompanied by a rising burden of age-related neurological disorders that significantly impact individuals, families, healthcare systems, and society. Neurodegenerative diseases are among the leading causes of disability and mortality in older adults and are expected to increase dramatically in prevalence over the coming decades [2]. Neurodegeneration refers to the progressive loss of neuronal structure and function, ultimately resulting in neuronal death. Common age-related neurodegenerative disorders include Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), and vascular dementia. These disorders share several pathological features, including abnormal protein aggregation, mitochondrial dysfunction, oxidative stress, synaptic impairment, and chronic neuroinflammation. While the specific mechanisms differ among diseases, accumulating evidence suggests that inflammatory processes within the central nervous system play a central role in disease development and progression. Historically, neuroinflammation was considered a secondary consequence of neuronal injury [3]. However, contemporary research indicates that persistent activation of the brain’s innate immune system actively contributes to neuronal degeneration. Microglial activation, astrocyte reactivity, cytokine production, and immune-mediated cellular damage have emerged as critical components of disease pathology. The interaction between aging, immune dysregulation, and neurodegeneration has therefore become a major focus of neurological research. This review explores the current understanding of neuroinflammation and its relationship with neurodegeneration in age-related neurological disorders [4]. The review examines underlying molecular mechanisms, disease-specific inflammatory pathways, biomarkers, therapeutic targets, and future directions in neuroinflammation research.

2. Neuroinflammation: Definition and Biological Significance

Neuroinflammation refers to the immune response occurring within the central nervous system (CNS) following injury, infection, toxic exposure, protein aggregation, or other pathological stimuli. Unlike peripheral inflammation, neuroinflammation involves specialized CNS immune cells, including microglia, astrocytes, oligodendrocytes, and infiltrating immune cells. Under physiological conditions, these cells maintain neural homeostasis and protect against pathogens. However, chronic activation can result in detrimental consequences for neuronal survival. Acute neuroinflammation may be beneficial by promoting tissue repair, debris clearance, and restoration of homeostasis [5], prolonged inflammatory responses can contribute to neuronal dysfunction and degeneration. Chronic neuroinflammation is characterized by sustained activation of immune pathways, excessive cytokine production, oxidative stress, and disruption of neuronal signaling networks. The aging brain exhibits increased susceptibility to neuroinflammatory processes due to immunosenescence, mitochondrial decline, accumulation of cellular damage, and impaired clearance of toxic proteins. Consequently, neuroinflammation has become recognized as a major driver of age-related neurological disease progression.

3. Cellular Mediators of Neuroinflammation

Microglia are the primary immune cells of the central nervous system and play a crucial role in neuroinflammatory responses. Under normal conditions, microglia continuously survey the neural environment and contribute to synaptic maintenance and tissue homeostasis. Upon activation, microglia release inflammatory mediators, including tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), nitric oxide, and reactive oxygen species. Astrocytes are another important component of neuroinflammatory responses. Activated astrocytes undergo morphological and functional changes, producing cytokines, chemokines, and inflammatory mediators that influence neuronal survival. Reactive astrocytes may exert either protective or harmful effects depending on the stage and severity of disease. Peripheral immune cells, including T lymphocytes, macrophages, and monocytes, may infiltrate the CNS when the blood–brain barrier becomes compromised [6]. Their presence can amplify inflammatory responses and contribute to disease progression. Interactions among microglia, astrocytes, neurons, and infiltrating immune cells create a complex inflammatory network that influences neurodegenerative outcomes.

4. Molecular Mechanisms Linking Neuroinflammation and Neurodegeneration

Several molecular pathways contribute to the relationship between neuroinflammation and neurodegeneration. One major mechanism involves excessive production of pro-inflammatory cytokines, which can impair synaptic function, disrupt neuronal signaling, and promote neuronal death. Oxidative stress is another important contributor. Activated immune cells generate reactive oxygen species (ROS) and reactive nitrogen species (RNS), which damage proteins, lipids, DNA, and mitochondria. Mitochondrial dysfunction further amplifies oxidative injury and inflammatory signaling, creating a vicious cycle of cellular damage [7]. The nuclear factor-kappa B (NF-κB) signaling pathway plays a central role in inflammatory gene regulation. Activation of NF-κB promotes the transcription of numerous cytokines, chemokines, and inflammatory enzymes involved in neurodegeneration. Similarly, activation of the NLRP3 inflammasome has been implicated in several neurodegenerative diseases by promoting the maturation and release of IL-1β and IL-18. Protein aggregation, including amyloid-beta plaques and tau tangles in Alzheimer’s disease or alpha-synuclein aggregates in Parkinson’s disease, can directly activate inflammatory pathways. These pathological proteins stimulate microglial activation and perpetuate chronic neuroinflammation.

5. Neuroinflammation in Alzheimer’s Disease

Alzheimer’s disease is the most common neurodegenerative disorder and the leading cause of dementia worldwide. Hallmark pathological features include extracellular amyloid-beta plaques and intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein. Recent studies have demonstrated that neuroinflammation plays a central role in Alzheimer’s disease pathology. Amyloid-beta deposits activate microglia and astrocytes, leading to sustained production of inflammatory cytokines. Chronic activation of these immune cells contributes to synaptic dysfunction, neuronal injury, and cognitive decline. Genetic studies have further highlighted the role of immune pathways in Alzheimer’s disease. Variants in genes such as TREM2, CD33, and CR1 influence microglial function and are associated with increased disease risk [8-9]. These findings support the concept that dysregulated immune responses significantly contribute to disease progression.

6. Neuroinflammation in Parkinson’s Disease

Parkinson’s disease is characterized by progressive degeneration of dopaminergic neurons in the substantia nigra and accumulation of alpha-synuclein-containing Lewy bodies. Neuroinflammatory responses are increasingly recognized as important contributors to disease progression. Activated microglia have been observed in affected brain regions of Parkinson’s disease patients. Elevated levels of inflammatory cytokines, oxidative stress markers, and activated immune pathways have been detected in both brain tissue and cerebrospinal fluid. Alpha-synuclein aggregates can directly stimulate microglial activation, leading to chronic inflammatory responses that exacerbate neuronal damage [10]. Emerging evidence suggests that peripheral immune dysfunction and gut-brain axis alterations may also contribute to neuroinflammation in Parkinson’s disease. These findings have generated considerable interest in immune-modulating therapeutic strategies.

7. Neuroinflammation in Other Age-Related Neurodegenerative Disorders

Neuroinflammation contributes significantly to the pathology of several other neurodegenerative diseases. In amyotrophic lateral sclerosis, activated microglia and astrocytes release toxic mediators that promote motor neuron degeneration. Elevated inflammatory markers have been associated with disease severity and progression. In Huntington’s disease, mutant huntingtin protein triggers inflammatory signaling pathways and microglial activation [11]. Similarly, vascular dementia is associated with cerebrovascular inflammation, endothelial dysfunction, and immune-mediated neuronal injury. Although each disease exhibits unique pathological features, chronic inflammation appears to be a common mechanism contributing to neuronal loss and functional decline.

8. Biomarkers of Neuroinflammation

Reliable biomarkers are essential for disease diagnosis, monitoring, and therapeutic evaluation. Several inflammatory biomarkers have been investigated in neurodegenerative disorders.

Common biomarkers include:

• Interleukin-1β (IL-1β)
• Interleukin-6 (IL-6)
• Tumor necrosis factor-alpha (TNF-α)
• C-reactive protein (CRP)
• YKL-40
• Soluble TREM2
• Glial fibrillary acidic protein (GFAP)

Advanced neuroimaging techniques, including positron emission tomography (PET), enable visualization of microglial activation in vivo. These technologies provide valuable insights into inflammatory processes occurring during disease progression.

9. Therapeutic Strategies Targeting Neuroinflammation

Targeting neuroinflammation has emerged as a promising therapeutic approach for neurodegenerative diseases [12]. Anti-inflammatory drugs, immunomodulatory therapies, monoclonal antibodies, and small-molecule inhibitors are currently being investigated. Potential therapeutic approaches include:

• Cytokine inhibitors
• NLRP3 inflammasome inhibitors
• Microglial modulators
• Antioxidant therapies
• Stem cell therapies
• Gene-based therapies
• Immunotherapy targeting pathological proteins

Lifestyle interventions such as regular physical activity, healthy dietary patterns, cognitive stimulation, and stress reduction may also exert anti-inflammatory effects and support neurological health.

10. Emerging Research Directions

Recent advances in genomics, transcriptomics, proteomics, and single-cell sequencing have significantly enhanced understanding of neuroinflammatory mechanisms. Precision medicine approaches are increasingly being explored to identify patient-specific inflammatory signatures and optimize therapeutic interventions [13-14]. Artificial intelligence and machine learning are facilitating the discovery of novel biomarkers and therapeutic targets [15-16]. In addition, research investigating the gut microbiome, extracellular vesicles, and neuroimmune communication pathways may reveal new opportunities for intervention. Future studies are expected to focus on identifying early inflammatory changes that occur before the onset of clinical symptoms, thereby enabling earlier diagnosis and treatment.

11. Challenges and Future Perspectives

The substantial progress, several challenges remain in understanding neuroinflammation and neurodegeneration. The complexity of neuroimmune interactions, disease heterogeneity, and limitations of experimental models continue to hinder therapeutic development [17-19]. Many anti-inflammatory interventions that demonstrated promise in preclinical studies have failed to produce significant clinical benefits. This discrepancy highlights the need for improved disease models and better understanding of disease-specific inflammatory mechanisms. Future research should emphasize longitudinal studies, biomarker validation, personalized therapeutic approaches, and integration of multi-omics technologies. Such efforts will improve understanding of disease pathogenesis and facilitate the development of effective neuroprotective therapies.

12. Conclusion

Neuroinflammation has emerged as a fundamental contributor to the pathogenesis of age-related neurodegenerative disorders. Chronic activation of microglia and astrocytes, excessive cytokine production, oxidative stress, mitochondrial dysfunction, and impaired immune regulation collectively promote neuronal injury and disease progression. Evidence from Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s disease, and vascular dementia highlights the central role of inflammatory pathways in neurodegeneration. Advances in molecular biology, neuroimaging, and biomarker discovery have improved understanding of neuroimmune interactions and identified promising therapeutic targets. Although significant challenges remain, modulation of neuroinflammatory processes represents a promising strategy for slowing disease progression and improving neurological outcomes. Continued research into the mechanisms linking inflammation and neurodegeneration will be critical for developing effective interventions that support healthy brain aging and reduce the burden of neurological disease.

References

1. Soraci, Luca, Andrea Corsonello, Ersilia Paparazzo, Alberto Montesanto, Francesco Piacenza, Fabiola Olivieri, Maria Elsa Gambuzza et al. “Neuroinflammaging: a tight line between normal aging and age-related neurodegenerative disorders.” Aging and Disease 15, no. 4 (2024): 1726.
2. Azam, S., Haque, M. E., Balakrishnan, R., Kim, I. S., & Choi, D. K. (2021). The ageing brain: molecular and cellular basis of neurodegeneration. Frontiers in cell and developmental biology, 9, 683459.
3. Abadin, Xenia, Cristina de Dios, Marlene Zubillaga, Elia Ivars, Margalida Puigròs, Montserrat Marí, Albert Morales et al. “Neuroinflammation in age-related neurodegenerative diseases: role of mitochondrial oxidative stress.” Antioxidants 13, no. 12 (2024): 1440.
4. Brahadeeswaran, S., Sivagurunathan, N., & Calivarathan, L. (2022). Inflammasome signaling in the aging brain and age-related neurodegenerative diseases. Molecular neurobiology, 59(4), 2288-2304.
5. Zhang, J., Xie, D., Jiao, D., Zhou, S., Liu, S., Ju, Z., … & Zhao, C. (2024). From inflammatory signaling to neuronal damage: Exploring NLR inflammasomes in ageing neurological disorders. Heliyon, 10(12).
6. Rea, I. M., Gibson, D. S., McGilligan, V., McNerlan, S. E., Alexander, H. D., & Ross, O. A. (2018). Age and age-related diseases: role of inflammation triggers and cytokines. Frontiers in immunology, 9, 586.
7. Ward, R. J., Dexter, D. T., & Crichton, R. R. (2015). Ageing, neuroinflammation and neurodegeneration. Front Biosci (Schol Ed), 7(1), 189-204.
8. Kujawska, M., Domanskyi, A., & Kreiner, G. (2021). common pathways linking neurodegenerative diseases—the role of inflammation. Frontiers in cellular neuroscience, 15, 754051.
9. Muzio, L., Viotti, A., & Martino, G. (2021). Microglia in neuroinflammation and neurodegeneration: from understanding to therapy. Frontiers in neuroscience, 15, 742065.
10. Schain, M., & Kreisl, W. C. (2017). Neuroinflammation in neurodegenerative disorders—a review. Current neurology and neuroscience reports, 17(3), 25.
11. Han, T., Xu, Y., Sun, L., Hashimoto, M., & Wei, J. (2024). Microglial response to aging and neuroinflammation in the development of neurodegenerative diseases. Neural Regeneration Research, 19(6), 1241-1248.
12. Su, Y., & Su, Z. (2025). Effects of exercise on neuroinflammation in age-related neurodegenerative disorders. European Journal of Medical Research, 30(1), 909.
13. Stephenson, J., Nutma, E., van der Valk, P., & Amor, S. (2018). Inflammation in CNS neurodegenerative diseases. Immunology, 154(2), 204-219.
14. Moyse, Emmanuel, Slavica Krantic, Nesrine Djellouli, Sébastien Roger, Denis Angoulvant, Camille Debacq, Victoire Leroy, Bertrand Fougere, and Amal Aidoud. “Neuroinflammation: a possible link between chronic vascular disorders and neurodegenerative diseases.” Frontiers in aging neuroscience 14 (2022): 827263.
15. Jin, R., Chan, A. K. Y., Wu, J., & Lee, T. M. C. (2022). Relationships between inflammation and age-related neurocognitive changes. International journal of molecular sciences, 23(20), 12573.
16. Mani, S., Wasnik, S., Shandilya, C., Srivastava, V., Khan, S., & Singh, K. K. (2025). Pathogenic synergy: dysfunction mitochondria and neuroinflammation in neurodegenerative diseases associated with aging. Frontiers in Aging, 6, 1615764.
17. Spittau, B. (2017). Aging microglia—phenotypes, functions and implications for age-related neurodegenerative diseases. Frontiers in aging neuroscience, 9, 194.
18. Ray, R., Juranek, J. K., & Rai, V. (2016). RAGE axis in neuroinflammation, neurodegeneration and its emerging role in the pathogenesis of amyotrophic lateral sclerosis. Neuroscience & Biobehavioral Reviews, 62, 48-55.
19. Hou, Yujun, Xiuli Dan, Mansi Babbar, Yong Wei, Steen G. Hasselbalch, Deborah L. Croteau, and Vilhelm A. Bohr. “Ageing as a risk factor for neurodegenerative disease.” Nature reviews neurology 15, no. 10 (2019): 565-581.